EJNMMI Research

Papers
(The TQCC of EJNMMI Research is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Nanobody: a promising toolkit for molecular imaging and disease therapy93
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review38
Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis35
A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease32
Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics28
Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics27
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients25
Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET24
The pons as reference region for intensity normalization in semi-quantitative analysis of brain 18FDG PET: application to metabolic changes related to ageing in conventional and digital control databa23
Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer23
CERMEP-IDB-MRXFDG: a database of 37 normal adult human brain [18F]FDG PET, T1 and FLAIR MRI, and CT images available for research22
Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients22
First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer21
Imaging modalities for diagnosis and monitoring of cancer cachexia21
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer20
The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.020
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer20
Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network19
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer19
Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study18
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET18
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients17
Detection of the sentinel lymph node with hybrid tracer (ICG-[99mTc]Tc-albumin nanocolloid) in intermediate- and high-risk endometrial cancer: a feasibility study17
Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET17
Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease17
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study17
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy17
First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor17
There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography17
Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.016
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer16
A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer16
L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas16
The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)16
Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT15
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation15
Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods15
99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle15
Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour15
An update on the use of image-derived input functions for human PET studies: new hopes or old illusions?15
Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases15
Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease15
[18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis14
18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy14
Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients14
Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis14
Evaluation of image quality with four positron emitters and three preclinical PET/CT systems13
[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma13
A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms13
Lung shunt fraction calculation using 99mTc-MAA SPECT/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors12
Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients12
A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroid12
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy12
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision12
Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images12
Whole-body [18F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation12
Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics12
FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET12
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging11
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy11
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-100711
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization11
[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study11
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma10
The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma10
Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy10
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients10
Magnetic nanoparticles in theranostics of malignant melanoma10
Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body 18F-FDG PET/CT scans10
Prospective data-driven respiratory gating of [68Ga]Ga-DOTATOC PET/CT10
In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-20110
The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis10
Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and revi10
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification10
Conscious rat PET imaging with soft immobilization for quantitation of brain functions: comprehensive assessment of anesthesia effects on cerebral blood flow and metabolism10
A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-62409
PET imaging of an optimized anti-PD-L1 probe 68Ga-NODAGA-BMS986192 in immunocompetent mice and non-human primates9
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy9
Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations9
A dedicated paediatric [18F]FDG PET/CT dosage regimen9
Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients9
Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer9
Automated and robust organ segmentation for 3D-based internal dose calculation9
Intraoperative [18F]FDG flexible autoradiography for tumour margin assessment in breast-conserving surgery: a first-in-human multicentre feasibility study9
The metabolic parameters based on volume in PET/CT are associated with clinicopathological N stage of colorectal cancer and can predict prognosis9
Direct reconstruction for simultaneous dual-tracer PET imaging based on multi-task learning9
Visualizing cellularity and angiogenesis in newly-diagnosed glioblastoma with diffusion and perfusion MRI and FET-PET imaging9
Sex correction improves the accuracy of clinical dopamine transporter imaging9
Feasibility of a drop-in γ-probe for radioguided sentinel lymph detection in early-stage cervical cancer9
In vitro and pilot in vivo imaging of 18 kDa translocator protein (TSPO) in inflammatory vascular disease9
Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors8
Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody8
Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation8
Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT8
18F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography8
Predictive value of 99mTc-MAA-based dosimetry in personalized 90Y-SIRT planning for liver malignancies8
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?8
PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer8
Post-reconstruction enhancement of [18F]FDG PET images with a convolutional neural network8
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example8
Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging8
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-2258
CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett’s esophagus8
Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body 68 Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer afte8
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness7
Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson’s disease7
Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors7
Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy7
A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides7
Impact of cerebral blood flow and amyloid load on SUVR bias7
Assessing the impact of different penalty factors of the Bayesian reconstruction algorithm Q.Clear on in vivo low count kinetic analysis of [11C]PHNO brain PET-MR studies7
Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma7
Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC7
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications7
Rationale for MYC imaging and targeting in pancreatic cancer7
Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine7
Clinical impact of digital and conventional PET control databases for semi-quantitative analysis of brain 18F-FDG digital PET scans7
Engineering a modular 44Ti/44Sc generator: eluate evaluation in preclinical models and estimation of human radiation dosimetry7
[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism7
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A7
Predicting the nature of pleural effusion in patients with lung adenocarcinoma based on 18F-FDG PET/CT7
Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study7
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE7
A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors7
In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study7
Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools7
Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice7
Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders7
0.059605121612549